Literature DB >> 10720499

Mucosal and systemic immunity against poliovirus in mice transgenic for the poliovirus receptor: the poliovirus receptor is necessary for a virus-specific mucosal IgA response.

A M Buisman1, J A Sonsma, T G Kimman, M P Koopmans.   

Abstract

In view of the planned eradication of poliovirus, the suitability of transgenic mice bearing the human receptor for poliovirus (PVRtg mice) as a nonprimate animal model to study mucosal immunity against poliovirus was investigated. After intraperitoneal (ip) priming followed by ip or oral booster with live poliovirus, PVRtg mice had detectable IgA and IgG responses. The IgA response was restricted to PVRtg mice and could not be induced by oral immunization. After ip priming, PVRtg mice did shed virus in the stool, whereas control mice did not. Moreover, the amount of virus shed in the stools of PVRtg mice that had an IgA response after immunization was significantly lower than that of nonimmunized mice. A virus-specific mucosal IgA response is dependent on expression of the poliovirus receptor and is influenced by the route of immunization and the virus strain. PVRtg mice are a suitable model for the study of poliovirus-specific immunity and protection against poliovirus infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720499     DOI: 10.1086/315326

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  2 in total

1.  Excretion of wild-type and vaccine-derived poliovirus in the feces of poliovirus receptor-transgenic mice.

Authors:  Hein J Boot; Daniella T J Kasteel; Anne-Marie Buisman; Tjeerd G Kimman
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

2.  Alternative inactivated poliovirus vaccines adjuvanted with Quillaja brasiliensis or Quil-a saponins are equally effective in inducing specific immune responses.

Authors:  Fernanda de Costa; Anna Carolina A Yendo; Samuel P Cibulski; Juliane D Fleck; Paulo M Roehe; Fernando R Spilki; Grace Gosmann; Arthur G Fett-Neto
Journal:  PLoS One       Date:  2014-08-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.